ROYALTY, LICENSE AND TERMINATION AGREEMENT RELATING TO LICENSE AND COLLABORATION AGREEMENT DATED JANUARY 6, 2017 BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND OVID THERAPEUTICS INC. MARCH 2, 2021Royalty, License and Termination Agreement • May 13th, 2021 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This Royalty, License and Termination Agreement (this “Agreement”) is made effective as of March 2, 2021 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”), and Ovid Therapeutics Inc., a company incorporated under the laws of the State of Delaware having its principal place of business at 1460 Broadway, New York, NY 10036, U.S.A. (“Ovid”). Ovid and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
